Jeremiah Hays
Family · Columbia, MONPI 1306499520
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.1% of the total across 210 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,993, 2.4 times the $848 reported in 2021. Among family clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 210 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$774
- AbbVie$736
- Astellas Pharma US Inc$447
- Convatec Inc.$321
- Aimmune Therapeutics, Inc.$252
- Takeda Pharmaceuticals U.S.A., Inc.$216
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,97990%
- Education$43910%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 33 | $774 |
| AbbVie(2 entities) | 38 | $736 |
| Astellas Pharma US Inc | 14 | $447 |
| Convatec Inc. | 10 | $321 |
| Aimmune Therapeutics, Inc. | 12 | $252 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $216 |
| Merck | 8 | $161 |
| Celltrion USA Inc. | 6 | $125 |
| Boston Scientific | 6 | $119 |
| Myovant Sciences Inc. | 6 | $112 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $107 |
| Ardelyx, Inc. | 4 | $68 |
| Ipsen Biopharmaceuticals, Inc | 3 | $58 |
| Medtronic | 1 | $57 |
| Lilly USA, LLC | 3 | $56 |
| Clarus Therapeutics Inc. | 3 | $56 |
| Alnylam Pharmaceuticals Inc. | 3 | $55 |
| Antares Pharma, Inc. | 4 | $52 |
| Phathom Pharmaceuticals, Inc. | 5 | $50 |
| Novartis | 2 | $46 |
| Pfizer | 3 | $45 |
| Accord Healthcare, Inc. | 2 | $42 |
| Dendreon Pharmaceuticals LLC | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Blue Earth Diagnostics | 2 | $38 |
| Sun Pharmaceutical Industries Inc. | 2 | $38 |
| Baxter Healthcare | 1 | $35 |
| Amgen | 2 | $34 |
| Bayer | 2 | $33 |
| Laborie Medical Technologies Corp. | 2 | $33 |
| Tolmar Pharmaceuticals, Inc. | 2 | $32 |
| Halozyme Inc | 2 | $31 |
| Urovant Sciences Inc | 2 | $28 |
| Bristol Myers Squibb | 1 | $17 |
| Gilead | 1 | $17 |
| Madrigal Pharmaceuticals | 1 | $16 |
| BD | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
How this compares
$4,418 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 353 | $206,954 |
| MyrbetriqMirabegron | 278 | $161,446 |
| Tamsulosin Hcl | 1,301 | $19,024 |
| ElmironPentosan Polysulfate Sodium | 13 | $17,970 |
| Methenamine Hippurate | 210 | $15,248 |
| Testosterone Cypionate | 361 | $9,395 |
| Finasteride | 682 | $8,753 |
| Mirabegron ErMirabegron | 14 | $8,641 |
| LinzessLinaclotide | 12 | $8,406 |
| Solifenacin Succinate | 138 | $8,253 |
| Potassium Citrate ErPotassium Citrate | 90 | $7,206 |
| Testosterone | 69 | $6,954 |
| Fosfomycin Tromethamine | 12 | $6,751 |
| Oxybutynin Chloride ErOxybutynin Chloride | 197 | $4,666 |
| Trimethoprim | 61 | $4,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $14 | $206,954353 claims |
| Astellas Pharma US IncMyrbetriq | $447 | $161,446278 claims |
| AbbVieLinzess | $736 | $8,40612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.
Other family in Columbia
- Marcy MarkesColumbia$92K
- Jennifer GriggColumbia$46K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.